Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the ...
To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.
Patients who live with CF are faced with a variety of health and lifestyle challenges. When might be the best time to talk ...
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...
Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosisTopline data expected in ...
Dr. Drucy Borowitz helped turn cystic fibrosis from a deadly childhood illness into a treatable condition, giving families ...
Shares of Arcturus Therapeutics Holdings fell sharply premarket amid fears about patient complications in the wake of a mid-stage trial of a biotech spray treatment for cystic fibrosis that had mixed ...
When I was diagnosed with cystic fibrosis at 43, I thought I was living on borrowed time. Now, at 75, I’ve learned that I am not defined by the odds.
Asian patients with non-cystic fibrosis bronchiectasis had a lower annualized exacerbation rate and less lung function ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback